Internasjonale forskjeller i metastatiske brystkreftutfall
Prosjekt
|Oppdatert
Sammendrag
Cancer recurrence or progression to metastatic disease represent two important outcomes that heavily influence survival and survivorship. At present, information on these outcomes is not routinely collected at cancer registries or other population-level data sources while they are critical in determining strategies to improve survivorship, cancer service requirement, and research priorities. Using high-quality cancer registry data from five selected high-income countries (U.S., Canada, Ireland, Norway, and the Netherlands), the aim of this international high-resolution study is, for the first time, to assess the true burden and survival from metastatic breast cancer (MBC) on the population-level. Clinical, pathological and patient-related determinants that might explain differences in international disparities in MBC outcomes will be investigated and the number of deaths from MBC that could potentially be postponed or avoided will be estimated.
Prosjektleder
Jan Franz Nygård, Folkehelseinstituttet
Prosjektdeltakere
Jan Franz Nygård, Kreftregisteret - Institutt for populasjonsbasert kreftforskning
Start
01.01.2020
Slutt
31.12.2024
Status
Pågående
Godkjenninger
Regionale komitéer for medisinsk og helsefaglig forskningsetikk (REK)
Prosjekteier/ prosjektansvarlig
Folkehelseinstituttet